Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.54 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.54 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.54 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.87 |
| ▸ | CA1 | P00915 | 3/20 | 0.59 |
| ▸ | CA2 | P00918 | 3/20 | 0.59 |
| ▸ | CA9 | Q16790 | 3/20 | 0.59 |
| ▸ | CA12 | O43570 | 2/20 | 0.59 |
| ▸ | CA7 | P43166 | 2/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.59 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.59 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL616715 | 0.93 | GAA (1.00) | GAACA1CA2CA9CA12 | |
| Hydrochloric Acid SCHEMBL7414277 | 0.91 | GAA (0.96) | GAACA1CA2CA9CA12 | |
| Sulfuric Acid SCHEMBL3629891 | 0.82 | GAA (0.58) | GAACA1CA2CA9CA12 | |
| SCHEMBL8030650 | 0.81 | GAA (0.67) | GAACA1CA2CA9CA12 | |
| SCHEMBL3334505 | 0.81 | GAA (0.67) | GAACA1CA2CA9CA12 | |
| SCHEMBL5314896 | 0.80 | SMN1; SMN2 (0.83) | GAACA1CA2CA9CA12 | |
| SCHEMBL28812692 | 0.79 | CA2 (0.62) | GAACA1CA2CA9CA12 | |
| SCHEMBL4737522 | 0.79 | GAA (0.69) | GAACA1CA2CA9CA12 | |
| Aminosalicylic Acid SCHEMBL3334502 | 0.79 | ALDH1A1 (0.79) | GAACA1CA2CA9CA12 | |
| SCHEMBL267165 | 0.79 | GAA (0.73) | GAACA1CA2CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9149530-B2 | Compositions and methods for enhancing active agent absorption | NEXUS PHARMA, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-8426466-B2 | Compositions and methods for enhancing active agent absorption | NEXUS PHARMA, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2150243-A2 | COMPOSITIONS AND METHODS FOR ENHANCING ACTIVE AGENT ABSORPTION | Nexus Pharma, Inc. (US) | 2010-02-10 | — | — | EP | disclosed |
| WO-2008144690-A2 | COMPOSITIONS AND METHODS FOR ENHANCING ACTIVE AGENT ABSORPTION | NEXUS PHARMA, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20070269494-A1 | Compositions and methods for enhancing active agent absorption | NEXUS PHARMA, INC. | 2007-11-22 | — | — | US | disclosed |
| US-20070269500-A1 | Compositions and methods for enhancing active agent absorption | NEXUS PHARMA, INC. | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070269494-A1 | Compositions and methods for enhancing active agent absorption | FABP2, SLC10A2, SI | CHRM1 746/4885SLC6A2 418/4885ADRA1A 768/4885 |
| US-20070269500-A1 | Compositions and methods for enhancing active agent absorption | FABP2, SLC10A2, SI | CHRM1 746/4885SLC6A2 418/4885ADRA1A 768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.